New strategies for targeting kinase networks in cancer

Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update

(2021) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Limited inhibition of multiple nodes in a driver network blocks metastasis

(2021) Ali Ekrem Yesilkanal et al.   eLife

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

(2021) Iris Simon et al.   Cancers

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

(2021) Steven P. Angus et al.   npj Breast Cancer

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting

(2020) Rona Yaeger et al.   CLINICAL CANCER RESEARCH

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

Combining microenvironment normalization strategies to improve cancer immunotherapy

(2020) Fotios Mpekris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

(2020) Ramesh K. Ramanathan et al.   Targeted Oncology

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

(2020) Charles Pottier et al.   Cancers

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

(2020) Praveen Vikas et al.   Frontiers in Oncology

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

(2020) João M. Fernandes Neto et al.   Nature Communications

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

(2020) Irem Ozkan-Dagliyan et al.   Cell Reports

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

(2020) Won Suk Lee et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

AKT and ERK dual inhibitors: The way forward?

(2019) Zhe Cao et al.   CANCER LETTERS

Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma

(2019) Justine V Cohen et al.   CLINICAL CANCER RESEARCH

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer

(2019) Joyce F. Liu et al.   GYNECOLOGIC ONCOLOGY

Control Theory Concepts for Modeling Uncertainty in Enzyme Kinetics of Biochemical Networks

(2019) Ljubisa Miskovic et al.   INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

(2019) Christopher A. Eide et al.   CANCER CELL

Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition

(2019) Meagan B. Ryan et al.   CLINICAL CANCER RESEARCH

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management

(2019) Isabelle Solassol et al.   Biomolecules

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

(2019) Shannon N. Westin et al.   GYNECOLOGIC ONCOLOGY

Estimation of clinical trial success rates and related parameters

(2018) Chi Heem Wong et al.   BIOSTATISTICS

A Convergence-Based Framework for Cancer Drug Resistance

(2018) David J. Konieczkowski et al.   CANCER CELL

Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies

(2018) Jill A. Gallaher et al.   CANCER RESEARCH

Mass Spectrometry–Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

(2018) Filip Mundt et al.   CANCER RESEARCH

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

(2018) Anthony W. Tolcher et al.   MOLECULAR CANCER THERAPEUTICS

Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2‐Amplified Colorectal Cancer

(2018) Marwan G. Fakih   ONCOLOGIST

BRAF/MEK Combo Approved for Melanoma

(2018)   Cancer Discovery

SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models

(2018) Carmine Fedele et al.   Cancer Discovery

Targeting Raf Kinase Inhibitory Protein Regulation and Function

(2018) Ali Yesilkanal et al.   Cancers

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

(2018) Angelina V. Vaseva et al.   CANCER CELL

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

(2017) Andrew A. Wylie et al.   NATURE

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer

(2017) Amanda E D Van Swearingen et al.   NEURO-ONCOLOGY

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

(2017) Robert S McNeill et al.   NEURO-ONCOLOGY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

(2017) Nicholas D. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

When less is more

(2017) Jocelyn Kaiser   SCIENCE

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

(2017) Jon S. Zawistowski et al.   Cancer Discovery

Implications of KRAS mutations in acquired resistance to treatment in NSCLC

(2017) Marzia Del Re et al.   Oncotarget

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer

(2017) S-U Woo et al.   Oncogenesis

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

(2016) Sarah J. Welsh et al.   EUROPEAN JOURNAL OF CANCER

Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?

(2015) Han Hsi Wong et al.   LANCET ONCOLOGY

An evidence-based knowledgebase of metastasis suppressors to identify key pathways relevant to cancer metastasis

(2015) Min Zhao et al.   Scientific Reports

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

(2015) Timothy J. Stuhlmiller et al.   Cell Reports

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

(2014) G. Kim et al.   CLINICAL CANCER RESEARCH

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

A framework for parameter estimation and model selection from experimental data in systems biology using approximate Bayesian computation

(2014) Juliane Liepe et al.   Nature Protocols

The dynamic nature of the kinome

(2013) Lee M. Graves et al.   BIOCHEMICAL JOURNAL

Parameter uncertainty in biochemical models described by ordinary differential equations

(2013) J. Vanlier et al.   MATHEMATICAL BIOSCIENCES

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia

(2013) Matthew J. Cooper et al.   PLoS One

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

(2012) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

ABC-SysBio--approximate Bayesian computation in Python with GPU support

(2010) J. Liepe et al.   BIOINFORMATICS

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2010) R. K. Jain et al.   CLINICAL CANCER RESEARCH

Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species

(2010) T.-R. Xu et al.   Science Signaling

Brustvolumenbestimmung anhand der 3-D-Oberflächengeometrie: Verifizierung der Methode mit Hilfe der Kernspintomographie / Breast volume assessment based on 3D surface geometry: verification of the method using MR imaging

(2008) Maximilian Eder et al.   Biomedical Engineering-Biomedizinische Technik

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE